For the quarter ended June 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $659.83 million, up 107% over the same period last year. EPS came in at $0.56, compared to -$2.21 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $448.44 million, representing a surprise of +47.14%. The company delivered an EPS surprise of +175.68%, with the consensus EPS estimate being -$0.74.While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...